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Abstract
Microglia are key players in the central nervous system in health and disease. Much pioneering research on microglia
function has been carried out in vivo with the use of genetic animal models. However, to fully understand the role of
microglia in neurological and psychiatric disorders, it is crucial to study primary human microglia from brain donors. We
have developed a rapid procedure for the isolation of pure human microglia from autopsy tissue using density gradient
centrifugation followed by CD11b-specific cell selection. The protocol can be completed in 4 h, with an average yield of
450,000 and 145,000 viable cells per gram of white and grey matter tissue respectively. This method allows for the
immediate phenotyping of microglia in relation to brain donor clinical variables, and shows the microglia population to
be distinguishable from autologous choroid plexus macrophages. This protocol has been applied to samples from over
100 brain donors from the Netherlands Brain Bank, providing a robust dataset to analyze the effects of age, post-mortem
delay, brain acidity, and neurological diagnosis on microglia yield and phenotype. Our data show that cerebrospinal fluid
pH is positively correlated to microglial cell yield, but donor age and post-mortem delay do not negatively affect viable
microglia yield. Analysis of CD45 and CD11b expression showed that changes in microglia phenotype can be attributed
to a neurological diagnosis, and are not influenced by variation in ante- and post-mortem parameters. Cryogenic storage
of primary microglia was shown to be possible, albeit with variable levels of recovery and effects on phenotype and
RNA quality. Microglial gene expression substantially changed due to culture, including the loss of the microglia-specific
markers, showing the importance of immediate microglia phenotyping. We conclude that primary microglia can be
isolated effectively and rapidly from human post-mortem brain tissue, allowing for the study of the microglial population
in light of the neuropathological status of the donor.
Keywords: Post-mortem human brain, Primary human microglia, Rapid cell isolation protocol, Primary
microglial cell culture, Biobanking
Introduction
Microglia are brain-resident phagocytic cells, which origin-
ate from a population of myeloid progenitors from the yolk
sac during embryonic development [16, 23, 35] and are
maintained through self-renewal without influx of periph-
eral cells during adult life [1, 4]. Microglia are key players in
central nervous system (CNS) homeostasis, fulfilling essen-
tial roles in neurodevelopment, adult synaptic plasticity,
and brain immunity [32, 34]. In the adult brain, microglia
act as surveyors of the local environment to sustain homeo-
stasis and are therefore highly sensitive to changes associ-
ated with damage, inflammation, or infection within and
outside the CNS. In order to interact with their environ-
ment, microglia exhibit a broad range of sensory mecha-
nisms and specific cellular responses, the outcome of which
can be both neuroprotective as well as a neurotoxic [22].
During the process of normal aging, the microglial
phenotype appears to shift to a primed or more active-
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prone state [22, 30], the main reasoning behind micro-
glia being linked to pathology in neurodegenerative
disorders such as Alzheimer’s disease (AD) [21], Parkin-
son’s disease (PD) [33], and multiple sclerosis (MS) [24].
Their role as possible contributors to disease has been
complemented by evidence for their involvement in the
pathophysiology of developmental and psychiatric disor-
ders, such as major depression disorder, bipolar disorder,
schizophrenia, and autism [3, 7], either through modula-
tion of neuroinflammation or neuronal plasticity. How-
ever, their role in disease pathology appears ambiguous
since microglia also display beneficial and restorative
functions [36].
Research on microglia function and their role in health
and disease has mostly been carried out ex vivo using im-
munohistochemistry and in vivo using murine models. The
isolation of microglia from the brains of various genetic
mouse models has greatly facilitated our understanding of
basic microglia characteristics in health and disease [9].
Nevertheless, these models are of limited value in relation
to human CNS disorders. Studies into human microglia
function have highlighted similarities but also crucial differ-
ences between mice and humans [38]. Added difficulty
comes in the form of various CNS disorders for which ani-
mal models are not available or fail to reconstitute import-
ant human symptoms. Therefore, to investigate the role of
microglia in human context it is crucial to study human
primary microglia.
In order to specifically study multiple aspects of hu-
man microglia, obtaining pure microglia populations
from post-mortem human brain samples is essential. To
this aim, we have adapted the human microglia isolation
method of Dick et al. [12], in turn based on a rat isola-
tion protocol [37], for the use of post-mortem human
brain tissue. This led to a procedure for the rapid isola-
tion of pure human microglia based on cell density sep-
aration and capture of CD11b-positive cells using
magnetic beads [25]. A major advantage of this isolation
procedure in comparison with generally used microglia
isolation methods [11] is the omission of effects due to
culture and adherence in the procedure, as it allows for
direct analysis of isolated microglia. Using this tech-
nique, we determined that based on membrane expres-
sion of CD45 and CD11b, microglia can be distinguished
from autologous peripheral macrophages based on fluor-
escence intensity [25]. Furthermore, we demonstrated
that microglia show a minimal response to lipopolysac-
charide (LPS), indicating a tight regulation of inflamma-
tory responses. Finally, we revealed differences in
microglial size, granularity, and CD45/CD11b expression
in white matter microglia from MS donors, when com-
pared to non-MS donors [26], showing that microglial
phenotype reflects neuropathological changes. Yet, to ef-
fectively study primary human microglia on a larger
scale, there is an urgent need for thorough validation of
available protocols and an understanding of the effects
of clinical diagnosis and ante- and post-mortem vari-
ables on isolated microglia.
Since the development of our procedure for the isola-
tion of human microglia in 2012 [25], we performed
microglia isolations from over a hundred brain donors
from the Netherlands Brain Bank. In addition to our
previously published method, we have also developed a
faster protocol that reduces the total isolation time,
while maintaining similar or higher viable cell yield.
Here we set out to validate the practical aspects of hu-
man post-mortem microglia isolations and describe the
effects of clinical diagnosis and ante- and post-mortem
variables on microglial purity and phenotype, such as
post-mortem delay (PMD) and cerebrospinal fluid (CSF)




Human brain tissue was obtained through the Netherlands
Brain Bank (www.brainbank.nl). The Netherlands Brain
Bank received permission to perform autopsies and to use
tissue and medical records from the Ethical Committee of
the VU University medical center (VUmc, Amsterdam, The
Netherlands). On average, the autopsies are performed
within 6 h after death. All donors have given informed con-
sent for autopsy and use of their brain tissue for research
purposes. The pH of the CSF was measured using a fluid-
based pH meter (Hanna Instruments, Nieuwegein, The
Netherlands), after rapid sampling of the CSF directly from
the lateral ventricles at the start of the autopsy. An over-
view of the clinical information and post-mortem variables
of all brain donors in this study is summarized in Table 1.
Human post-mortem microglia isolation
At autopsy, corpus callosum or subcortical white matter
(WM) and occipital cortex grey matter (GM) was dissected,
collected in Hibernate A medium (Invitrogen, Carlsbad,
USA) and stored at 4 °C until processing. Microglia isola-
tions were performed as described previously [25], or
through a recently implemented adaptation of this protocol,
showing similar or higher yield, while reducing total proto-
col time to approximately 4 h. The current isolation method
and differences with the previous method are depicted, at a
glance, in Fig. 1. A point by point, detailed description of
the current protocol can be found in the supplemental in-
formation. Mechanical dissociation was performed by
meshing over a metal tissue sieve, after removal of the men-
inges (GM) or cutting tissue into fine pieces using a scalpel
(WM). Further dissociation was performed by passing the
suspension through a 10-ml pipette, followed by enzymatic
dissociation with 300 U/ml collagenase 1 (Worthington,
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Lakewood, USA) for 60’ (previous method) or with trypsin
(Invitrogen) at a final concentration of 0.125% for 45’
(current method) in Hibernate A medium at 37 °C on a
shaking platform. Both digestions were incubated in the
presence of 33 μg/ml DNAseI (Roche, Basel, Switzerland).
The digestion was resuspended 10x with a 10-ml halfway
the digestion time. Heat inactivated fetal calf serum (FCS,
Invitrogen) was added to quench trypsin activity and the
cell suspension was centrifuged for 10 min at 1800 rpm and
4 °C. After discarding the supernatant, the cell pellet was re-
suspended in cold DMEM (Invitrogen), supplemented with
10% FCS, 1% Penicillin-Streptomycin (Pen-Strep, Invitro-
gen), and 1% gentamycin (Invitrogen), and passed through a
100-μm tissue sieve. After the direct addition of 1/3 volume
of cold Percoll (GE Healthcare, Little Chalfont, UK) and
centrifugation for 30’ at 4000 rpm and 4 °C the interphase
containing microglia was transferred to a new tube (discard-
ing the myelin and erythrocyte layers) and washed two
times in DMEM supplemented with 10% FCS, 1% Pen/
Strep, 1% gentamycin, and 25 mM Hepes (Invitrogen).
Negative selection of granulocytes (previous method only)
and positive selection of microglia with respectively anti-
CD15 and anti-CD11b conjugated magnetic microbeads
(Miltenyi Biotec, Cologne, Germany) was done by magnetic
activated cell sorting (MACS) according to the manufac-
turer’s protocol. Briefly, cells were incubated with 10 μl
CD15 microbeads for 15 min at 4 °C, washed, resuspended
in beads buffer (0.5% BSA, 2 mM EDTA in PBS pH 7.2)
and transferred to an MS column placed in a magnetic
holder. The flow-through containing unlabeled cells was
collected, washed and subsequently incubated with 20 μl
CD11b microbeads for 15 min at 4 °C. Cells were then
washed and placed on a new MS column in a magnetic
holder. The CD11b+ cell fraction was eluted from the col-
umn by removing the column from the magnet, adding
beads buffer, and emptying the column with a plunger. Vi-
able cells were then counted using a counting chamber and
used as described in downstream analyses. The isolation of
macrophages was performed using choroid plexus tissue
dissected from the lateral ventricle, using the same method
as for WMmicroglia.
Flow-cytometric analysis
The CD11b + cell fraction was evaluated for proper separ-
ation of microglia from other cell types by flow cytometry
for CD45 (FITC-labeled, Agilent, Santa Clara, USA),
CD11b (PE-labeled, eBioscience, San Diego, USA), and
CD15 (APC-labeled, Biolegend, San Diego, USA). For
CD45 and CD11b, appropriate isotype controls were regu-
larly included to assess background levels of fluorescence.
Cells were incubated with antibodies in beads buffer, on
ice, for 30’. Viability of the cells was analyzed using the fix-
able viability dye Efluor 780 or 7-AAD (eBioscience). For
spiking the microglia populations, macrophages where la-
beled with far red celltracker (Invitrogen) in PBS (1:1000)
for 5 min and washed twice with PBS. Fluorescence was
measured on either a FACSCalibur or a FACSCanto II
machine (both BD biosciences, Franklin Lakes, USA) and
analyzed with FlowJo software (Treestar, Ashland, USA).
For CD45 and CD11b geometric mean comparisons with
post-mortem parameters, only data from the FACS-
Calibur was included.
Cell culture
Microglia were cultured in DMEM/F-12 medium (Invitro-
gen), supplemented with 10% FCS and 1% Pen-Strep and
cultured in plates coated with poly-L-lysine (Invitrogen).
Myelin phagocytosis was assessed as described previously
[20]. In short, microglia were incubated for 48 h with
pHrodo-labeled myelin (10 μg/ml) from a myelin pool
containing myelin from 12 donors without neurological
abnormalities. All cultures described in the data are de-
rived from white matter samples, as cortical microglia did
not result in reproducible cultures. To assess the effect of
cryogenic storage and subsequent thawing of primary
microglia, cells were resuspended in ice-cold mixture of
medium and FCS (1:1), containing 10% dimethyl sulfoxide
(DMSO, Sigma, St. Louis, USA), placed in a cryogenic
container (Nalgene, Thermo Fischer, Waltham, USA) with
2-propanol, and stored overnight in a −80 °C freezer.
Cryovials were then transferred to a liquid nitrogen tank.
Cells were thawed by slowly adding cold complete RPMI
medium (Invitrogen) containing 20% FCS, after 20 min at
Table 1 Summary of clinical variables of brain donors used
Diagnosis Number Gender (F/M) Age ± SD PMD ± SD (hours) CSF pH ± SD Total time until processing ± SD
Control 43 1.69 80.91 ± 12.09 6.01 ± 1.31 6.52 ± 0.40 20.01 ± 8.88
AD 17 1.83 80.29 ± 9.92 5.29 ± 0.87 6.35 ± 0.19 19.71 ± 10.75
FTD 6 2 71.50 ± 7.09 5.53 ± 1.62 6.35 ± 0.20 28.44 ± 21.31
MS 32 1.13 65.31 ± 12.15 9.21 ± 1.68 6.46 ± 0.24 20.61 ± 10.01
PD 23 0.53 76.96 ± 10.12 5.77 ± 1.27 6.52 ± 0.24 22.48 ± 8.90
Other 14 0.78 70.25 ± 12.28 6.92 ± 2.77 6.49 ± 0.23 20.33 ± 5.22
All 135 1.17 74.87 ± 12.88 6.71 ± 2.13 6.47 ± 0.30 20.80 ± 10.47
AD Alzheimer’s disease, FTD fronto-temporal dementia, MS multiple sclerosis, PD Parkinson’s disease, OD other diagnoses (major depression, bipolar disease, neuro-
myelitis optica, progressive supranuclear palsy), F female, M male, SD standard deviation
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room temperature, cells were washed using warm
complete RPMI and either lysed for RNA isolation or ana-
lyzed directly using flow cytometry.
RNA isolation and gene expression analysis
Acutely isolated primary microglia were taken up in 1 ml
TRIsure (Bioline, London, UK) and stored at −80 °C for
further processing. RNA isolation was carried out
according to manufacturer’s protocol using phase separ-
ation by addition of chloroform and centrifugation,
followed by overnight precipitation in isopropanol at −20 °
C. RNA concentration was measured using a Nanodrop
(ND −1000; NanoDrop Technologies, Rockland, DE,
USA) and RNA integrity was assessed using a Bioanalyzer
(2100; Agilent Technologies, Palo Alto, CA, USA). cDNA
synthesis was performed using the Quantitect reverse
transcription kit (Qiagen, Hilden, Germany) according to
manufacturer’s instructions, with a minimal input of
200 ng total RNA. Quantitative PCR (qPCR) was per-
formed using the 7300 Real Time PCR system (Applied
Biosystems, Foster City, USA) using the equivalent cDNA
amount of 1–2 ng total RNA used in cDNA synthesis.
SYBRgreen mastermix (Applied Biosystems) and a 2
pmol/ml mix of forward and reverse primer sequences
were used for 40 cycles of target gene amplification. An
overview of forward and reverse sequences for each gene
can be found in Additional file 1: Table S1. Expression of
target genes was normalized to the average cycle threshold
of GAPDH and EF1a. Cycle threshold values were
assessed with SDS software (Applied Biosystems).
Statistical analysis
Data analysis was performed using Graphpad Prism soft-
ware (v6 Graphpad Software, La Jolla, CA, USA). Results
are shown as mean with standard error of the mean, and
statistical analysis was performed using either parametric
or non-parametric testing, based on the outcome of the
Shapiro-Wilk normality test. The applied test for each
calculated value is described in the figure legends.
Results
Isolation and characterization of microglia from post-
mortem CNS tissue
The isolation of viable microglia from post-mortem hu-
man CNS tissue has been described by our group previ-
ously [25]. For the data used in this study, we have used
both the published protocol as well as an adapted ver-
sion that is faster (~4 in place of ~5 h) in which collage-
nase is replaced by trypsin, and CD15 depletion is
omitted. The basic steps of the protocol and the aspects
that differ between both protocols are depicted in Fig. 1.
The cell capture in both methods relies on the mem-
brane expression of CD11b, which is also present on
perivascular and infiltrated macrophages in the CNS. To
investigate the differences between macrophages and
microglia from the same donor, we included choroid
plexus (CP) macrophages. To differentiate between the
two populations of cells, CP-derived CD11b+ cells were
labeled with a fluorescent cell tracker. To ensure that
the labeling method did not alter the fluorescence inten-
sity of CD45 and CD11b antibodies, unlabeled and la-
beled CP macrophages were compared, showing no
Fig. 1 Microglia isolation method at a glance Depicted are the two
similar methods through which microglia were isolated from post-
mortem brain tissue. CNS samples were dissected from either occipital
cortex (GM), corpus callosum (WM), or subcortical WM. Mechanical
disruption of tissue was performed using scalpel (WM) or tissue sieve
(GM). Dissociated tissue was then subjected to enzymatic digestion,
using DNAse I and either collagenase I (previous method) or trypsin
(current method), for 1 h and 45 min respectively. The resulting single
cell suspension was subjected to gradient separation using Percoll. The
glial cell fraction was extracted, washed, and subjected to CD11b +
purification using magnetic beads. CD11b + cells were eluted by
removing the column from the magnet and flushing the column
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change in CD45 and CD11b fluorescence (Fig. 2a). Fur-
thermore, we observed no APC/cell tracker+ cells in the
CD11b+ population isolated from WM (Fig. 2b). Repre-
sentative FACS plots showing the gating strategy to in-
vestigate only viable cells, including assessment of
background fluorescence using isotype controls, is
shown in Additional file 1: Figure S1. Spiking the WM
CD11b+ cells with labeled CP CD11b+ cells enabled us
to stain a combined population of WM and CP cells for
CD45 and CD11b, while allowing separation of the pop-
ulations based on APC+ (Fig. 2c). Comparing the size
and granularity of both cell populations in one pool of
cells identified CD11b+ cells from WM to have different
population characteristics compared to CD11b+ cells
from CP, showing the macrophages to be larger and
more granular (Fig. 2d). Furthermore, CP-derived mac-
rophages clearly showed a higher expression of CD45
and CD11b, when compared to WM-derived cells
(Fig. 2e). Quantification of the same analyses from seven
different donors with different neurological diagnoses
showed that the observations regarding CD45 (avg.
190.8% higher expression levels; Fig. 2f ), and CD11b
(avg. 106.4% higher expression levels; Fig. 2g) are con-
sistent for all investigated donors. We conclude that
microglia can be reliably isolated from post-mortem hu-
man CNS tissue, without apparent macrophage contam-
ination due to the fact that a large reservoir of
macrophages is not present in the CNS parenchyma.
Viable microglia yield from white and grey matter
correlates with CSF pH
Since post-mortem microglia isolations were performed
on brain samples from varying neurological disease and
control donors, we first assessed the differences between
the various groups of donors with respect to age, PMD,
and CSF pH. Only the MS donor group showed a sig-
nificant deviation from other groups in age (Fig. 3a) and
PMD (Fig. 3b), whereas no significant differences were
observed in CSF pH at autopsy between groups. (Fig. 3c).
The difference in PMD is explained by the longer aut-
opsy protocol for MS donors in which MRI-guided dis-
section is needed to separate normal-appearing WM
(NAWM) from lesioned areas [10], whereas the differ-
ence in age is explained by mortality at a younger age in
MS. We then combined data from all isolations, which
clearly showed a higher yield of viable microglia per
gram WM compared to GM tissue (Fig. 3d). This com-
bined graph also shows the high donor-to-donor vari-
ability in microglia yield, in both WM and GM
isolations. Colors separating the isolations performed
using the two described methods showed that the
current trypsin method produced the highest yields, al-
though the average yield between the two methods is
not significantly different (Additional file 1: Figure S2).
Since the region-specific difference in microglia yield
could be caused by an inherent difference between WM
and GM microglia, we separately analyzed isolations from
WM and GM to correlate with donor clinical parameters.
We first analyzed the influence of a neurological diagnosis
on microglia yield. Although both the AD and FTD groups
showed lower WM microglia yield averages compared to
the control, MS, and PD groups (Fig. 3e), the average num-
ber of microglia isolated from WM and GM (Fig. 3f) was
not significantly different between groups. We next ana-
lyzed the effect of donor age, PMD, and CSF pH on micro-
glia yield. For WM microglia isolations, we observed a
significant correlation of viable microglia yield with CSF
pH (Fig. 3g), but no correlation with either PMD (Fig. 3h)
or age (Fig. 3i). Although the average yield from GM micro-
glia isolations was much lower than those from WM, we
observed a similar significant correlation of GM microglia
yield with CSF pH (Fig. 3j) and similarly no correlation with
either PMD (Fig. 3k) or age (Fig. 3l). Besides investigating
PMD, we also included the total time until tissue processing
(PMD+ time until isolation; averaging 20.8 h over all isola-
tions) in our analysis, which did not show any correlation
to microglia yield (Additional file 1: Figure S3).
Combined, our data encompassing microglia isolations
from over 100 donors clearly shows a robust effect of
CSF pH, shown to reflect cortical pH at autopsy [19], on
viable microglia yield from post-mortem brain tissue.
We have analyzed the clinical information of all donors
to determine which variables correlate with CSF pH. In
our donor group, the cause of death, often reflecting the
agonal state of the donor before passing, is associated
with CSF pH (Additional file 1: Figure S4) and shows
that the average CSF pH is significantly lower in donors
that suffered from cachexia or pneumonia before death,
compared to donors that underwent euthanasia.
Changes in microglia expression of CD45 and CD11b are
mainly attributable to differences between grey and
white matter, and neurological diagnosis
In order to investigate whether microglia show an altered
phenotypical state when isolated from different donor
groups, due to varying levels of CSF pH, or under the influ-
ence of post-mortem variables like PMD, we performed
minimal phenotyping of the isolated microglia. We previ-
ously showed increased CD45 expression by microglia de-
rived from MS NAWM compared to non-MS WM [26] as
well as by WM microglia isolated from donors with a high
degree of peripheral inflammation [25]. Using an extended
group of non-demented controls and MS donors, we con-
firm the elevated CD45 expression in microglia from WM
of MS donors (Fig. 4a). CD11b expression was also elevated
in microglia from WM of MS donors, but did not reach
significance (p = 0.067). The same analysis of CD45 and
CD11b expression of GM microglia from MS and control
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donors showed no difference in mean fluorescence
(Additional file 1: Figure S5). Therefore, to exclude any ef-
fects of disease-related changes in microglia activation, we
have only included isolations performed on non-demented
control donor material in the following analyses. Using
CD45 and CD11b immunoreactivity as a readout for
Fig. 2 Isolated microglia from post-mortem human CNS tissue are distinguishable from autologous macrophages. a FACS plot showing non-labeled (red)
and far red cell tracker-labeled (blue) populations of CP-derived macrophages, CD11b/CD45 expression for both populations are shown in the FACS plot of
the corresponding number. b FACS plot showing a non-labeled population of WM microglia, note the absence of cell tracker signal. c FACS plot showing
a mixed population of cell tracker-labeled CP macrophages and non-labeled WM microglia, CP-derived macrophages are clearly separated by cell tracker
labeling. d Contour plot showing the forward (FSC-A) and sideward (SSC-A) scatter distribution of non-labeled WM microglia (red) and cell tracker-labeled
CP macrophages (blue), showing distinct population size and granularity for each group. e The same population of mixed cells as in C, showing CD11b
and CD45 immunolabeling, showing increased staining for both markers in CP macrophages (blue) compared to WM microglia (red). f-g Quantification of
the same cell tracker labeling strategy from seven brain donors shows that CD11b and CD45 geomean is increased in CP macrophages compared to WM
microglia for all isolations (paired t-test). **p value < 0.01, ***p value < 0.001
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microglial activation state, we analyzed microglia isolated
from either WM or GM tissue. Interestingly, we observed a
significantly lower membrane expression of CD45 of micro-
glia isolated from GM, when compared to WM-derived
microglia (Fig. 4b), whereas CD11b expression is not
significantly different (Fig. 4c). Since we also observed a dif-
ference in microglia yield from both regions, we separately
investigated the effect of clinical and post-mortem parame-
ters on microglia from WM and GM isolations. The mem-
brane expression of CD45 and CD11b of microglia isolated
Fig. 3 Viable microglia yield is correlated with CSF pH, not age or PMD. a-c Scatterplots showing the distribution of age, PMD, and CSF pH across
donor groups. The MS donor group shows significant differences in both age and PMD compared to other groups (one way ANOVA, Dunn’s
multiple comparison test). Note that CSF pH is not related to neurological diagnosis. d The number of microglia isolated per gram tissue is higher
in WM compared to GM isolations (unpaired Mann-Whitney test). Isolations performed using the previous method are denoted in red, those using
the current method in blue, continued in following graphs. e-f Microglia yield per gram of WM or GM tissue from different neurological groups
shows no differences due to diagnosis (one way ANOVA, Dunn’s multiple comparison test). g-i Microglia yield from WM tissue shows a significant
positive correlation with CSF pH, but not with PMD or age (Spearman correlation). j-l Microglia yield from GM tissue shows a significant positive
correlation with CSF pH, but not with PMD or age (Spearman correlation). *p value <0.05, **p value < 0.01, ***p value < 0.001, ****p value < 0.0001
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from WM tissue did not correlate significantly with either
CSF pH, PMD, or age (Fig. 4d-i). The CD45 expression pat-
tern for microglia isolated from GM was comparable to
that of WM microglia, showing no significant correlation
with any of the parameters investigated (Fig. 4j-l). In micro-
glia isolated from GM, CD11b expression shows no correl-
ation with CSF pH or age (Fig. 4m, o). Differently from
WM microglia however, CD11b expression in GM micro-
glia significantly correlates with increasing PMD (Fig. 4n).
We have also included total time until tissue processing in
our analysis, showing no correlation with either CD45 or
CD11b expression (Additional file 1: Figure S6).
Taken together, our data show that microglial CD45
expression clearly differs between cells isolated from
WM or GM. Average CD45 expression on microglia iso-
lated from either WM or GM is unrelated to CSF pH,
PMD, age, and population viability. We show a similar
absence of correlations for CD11b in both GM and WM
microglia, with the only exception being that GM micro-
glia showed increasing CD11b expression with increas-
ing PMD. By combining data of both microglia isolation
methods, we also observed a significant increase in both
CD45 and CD11b expression of GM microglia isolated
using the current method, compared to the previous
protocol (Additional file 1: Figure S7). This difference
was not observed for WM microglia.
In vitro applications of primary human microglia and
effects of cryogenic storage
To expand the possible research applications of primary hu-
man microglia, we investigated the possibility to cryogeni-
cally store microglia for biobanking purposes and their
potential for (long-term) in vitro culture. Using poly-L-
Lysine as a culture substrate, we found that primary micro-
glial cultures show a slightly ramified morphology and can
be maintained for 5 days in vitro (DIV) (Fig. 5a) and 10
DIV (Fig. 5b) without apparent signs of proliferation or cell
death. Accordingly, immunocytochemistry for proliferation
marker Ki-67 only sporadically decorated microglia nuclei
(Additional file 1: Figure S8). All microglial cultures were
derived from WM samples, as microglia cultures from GM
isolations showed no adherence or outgrowth past 2 days in
culture. Microglia retain phagocytic function after 5 DIV, as
evidenced by the uptake of pHrodo-labeled myelin (Fig. 5c).
How the cultured microglial phenotype compares to the
phenotype directly after isolation however, has not been ad-
dressed to date. We therefore used microglia isolated from
four different WM donors, isolated RNA either directly
after isolation or after 4 days of basal culture, and investi-
gated the change in gene expression from acute to cultured
microglia for each donor (Fig. 5d). Of all investigated genes,
only the macrophage marker and lipopolysaccharide co-
receptor CD14 was significantly upregulated after 4 days.
Interestingly, the microglia/macrophage markers purinergic
receptor P2Y12 (P2RY12), fractalkine receptor (CX3CR1),
and CD11b were all significantly decreased after 4 days.
Moreover, the pro-inflammatory cytokine interleukin 1 beta
(IL-1b) showed an increase in expression, but did not reach
significance, and immune-activated genes were downregu-
lated, including pro-inflammatory tumor necrosis factor
(TNF), glutamate aspartate transporter (GLAST), MHC
class II subunit HLA-DRA, Fc gamma receptor IIIa
(CD16a), and anti-inflammatory interleukin 10 (IL-10) and
transforming growth factor beta (TGFβ). Gene expression
of interleukin 1 alpha (IL-1α), chemokine C-C motif che-
mokine ligand 3 (CCL3), interleukin 6 (IL-6), CD45, and
the CD200 receptor (CD200R) was unchanged. Using this
selected set of genes, it becomes apparent that microglia
undergo phenotypical changes during culture.
Since RNA analysis directly after isolation is important to
accurately relate microglial phenotype to the in situ state of
the tissue, we analyzed whether RNA yield is constant be-
tween donors. We found a significant correlation between
the number of viable cells used and the RNA yield obtained
(Fig. 5e). Finally, we analyzed the potential to cryogenically
store acutely isolated microglia, and the effect of a freeze-
thaw cycle on RNA integrity and minimal phenotype. The
average recovery rate of viable cells from frozen samples
was 27%, although highly variable (±22.7%, Fig. 5f). We an-
alyzed the RNA integrity (RIN) from RNA extracted from
microglia immediately after isolation, and after cryogenic
storage, from the same donors. Although RIN values were
slightly decreased, we found no significant decrease of RIN
values after thawing and RIN values did not drop below 6,
reflecting usable mRNA in many applications (Fig. 5g). We
furthermore analyzed CD45 and CD11b expression on
(See figure on previous page.)
Fig. 4 Microglia phenotype in relation to diagnosis and donor variables. a Fluorescence geometric means for CD45 and CD11b of microglia isolated from
MS or control WM tissue. CD45 expression is significantly higher, CD11b expression does not reach significance (unpaired t test). Isolations performed using
the previous method are denoted in red, those using the current method in blue, continued in following graphs. b-c Fluorescence geometric mean for
CD45 and CD11b expression of microglia from WM and GM from non-demented control donors only. CD45 expression but not CD11b expression of WM
microglia is increased compared to GM microglia (Mann-Whitney test). d-f Correlation plots of fluorescence geometric mean of CD45 expression by WM
microglia show no significant correlation with CSF pH, PMD, or age (Pearson correlation). g-i Correlation plots of fluorescence geometric mean of CD11b
expression by WM microglia show no significant correlation with CSF pH, PMD, or age (Pearson correlation). j-l Correlation plots of fluorescence geometric
mean of CD45 expression by GM microglia show no significant correlation with CSF pH, PMD, or age (Pearson correlation). m-o Correlation plots of
fluorescence geometric mean of CD11b expression by GM microglia shows a significant positive correlation with PMD, but not with CSF pH or age
(Pearson correlation). ***p value < 0.001, ****p value < 0.0001
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viable microglia before and after thawing. CD11b expres-
sion was not significantly affected by cryogenic freezing and
thawing (Fig. 5h), but CD45 expression was increased in
thawed microglia compared to acutely analyzed cells, pos-
sibly reflecting ongoing cell activation or the selective loss
of cells with low CD45 expression. Thus, albeit a small
sample size, we show that microglia can be cryogenically
frozen and stored for biobanking purposes while
maintaining the possibility to phenotype using flow cytome-
try or to analyze gene expression. Furthermore, microglia
can be cultured for multiple days, but show profound
changes in their gene expression profile due to culture.
Discussion
In a time-span of 5 years, over a hundred human primary
microglia isolations have been performed on post-mortem
Fig. 5 Culture and cryogenic storage of human primary microglia. a-b Representative phase contrast images of WM microglia under basal culture
conditions showing cells with a slightly ramified morphology cultured for 5 days and 10 days respectively (x200). c Phase contrast image (x100) of WM
microglia incubated with pHrodo-labeled myelin for 48 h at 5 DIV. Superimposed red fluorescence signal shows labeled myelin in phagosomes. d Gene
expression analysis of microglia after 4 DIV compared to acutely lysed cells, expressed as fold change from acute (Mann-Whitney tests, n= 4). e Correlation
plot of RNA yield with starting number of microglia (Spearman correlation). f Linked scatterplot showing the recovery of viable microglia after cryogenic
storage. Cells from both WM and GM were used (n= 15). g RNA integrity of samples from cryogenically stored microglia is not significantly decreased
compared to acutely lysed samples (Wilcoxon matched-pairs test). h Fluorescence geometric mean of CD45 and CD11b expression of WM microglia
before and after cryogenic storage shows that CD45, but not CD11b expression is increased due to freezing (Wilcoxon matched-pairs test). *p value <0.05
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human brain samples. Analyzing the results of these ef-
forts, we here confirm that human microglia can be read-
ily isolated from post-mortem CNS tissue based on the
membrane expression of CD11b, that microglia are distin-
guishable from macrophages, and that the yield of viable
microglia is linked to the acidification of the CNS at time
of autopsy. Strikingly, neither age, PMD, nor neurological
diagnosis was correlated with viable microglia yield. The
microglia phenotype from control donors, as assessed by
CD45 and CD11b expression, was not correlated with
brain acidity, donor age, or PMD. We did observe a robust
effect of clinical MS diagnosis on CD45 expression, and to
a lesser extent on CD11b expression. This finding is of
great importance to any study aimed at linking changes in
microglial phenotype to a neurological diagnosis. Finally
we show that isolated microglia are suitable for culture
and cryogenic storage, but provide a cautionary note re-
garding the changes in microglia gene expression profile
due to culture. In summary, the most important conclu-
sion drawn from this study is that after rapid isolation,
changes in microglial phenotype can be readily attribut-
able to neurological disease parameters, rather than
reflecting uncontrollable donor parameters like age, PMD,
idle tissue time, or CNS acidity. This finding is of critical
importance to published and future studies implementing
the characterization of purified microglia.
The use of purified human microglia to study patho-
genic mechanisms of various neurological disorders is
relatively new. So far, only a small number of publica-
tions exist that describe a microglial phenotype, studying
acutely isolated cells with flow cytometry or gene ex-
pression analysis, in relation to clinical diagnosis. Our
group has previously shown that WM microglia isolated
from donors with peripheral inflammation [25] and do-
nors diagnosed with MS [26] display increased size,
granularity, and CD45 expression when compared with
microglia derived from control donors. Similar findings
exist for glioblastoma-derived microglia [29]. These find-
ings clearly demonstrate the potential of purified micro-
glia to shed light on neurological disease processes.
There is a growing interest in the use of primary glial
cells. A protocol was recently described for the acute
purification of human astrocytes from human cortex
[40], representing the first description of the molecular
profiles for human astrocytes from healthy and tumor
tissue, as well as showing a clear distinction between
cells from human and mouse origin. Although the ad-
vent of genetic animal models resulted in valuable tools
to study microglia phenotype and function in animal
models of neurological disease [39], the use of human
primary cells to study human CNS disorders should gain
more traction in the near future. Inevitably, studies that
make use of purified human microglia will encounter
high inter-donor variation in both cellular yield and
experimental read-out. This study, using a relatively
large donor sample size is therefore ideally suited to de-
scribe donor variables that should be taken into account
when analyzing the experimental read-out parameters.
Microglia yield
Microglia yield is an important factor to address when
considering the feasibility of experiments using human
microglia. While we did not find any relation of donor
age or neurological diagnosis with the cellular yield per
gram of brain tissue, CSF acidity at the time of autopsy
was a strong indicator of total yield. This finding is in
line with previously reported findings on microglia yield
using a similar purification method [29]. Interestingly,
the same authors reported similar yields from WM, GM,
and mixed samples, whereas we observed a clear differ-
ence in the number of cells that can be obtained per
gram of WM and GM tissue. This finding could reflect a
difference in microglia density between WM and GM re-
gions, an observation which has been reported using hu-
man post-mortem immunohistochemistry in control
brain tissue [28]. Alternatively, a regional difference
might exist in the microglial sensitivity to the isolation
method. The discrepancy between both studies could be
explained by the difference in total sample size. In our
donor population, we did not find a correlation between
CSF pH and neurological diagnosis or age. As CNS acid-
ity has been shown to relate to agonal state and tissue
quality [15], we analyzed our donor population accord-
ingly, and found that the cause of death relates to CSF
pH. Donors suffering from cachexia or pneumonia be-
fore death showed lower CSF pH than donors that
underwent euthanasia. The total microglia yield was not
affected by variations in PMD or the total time after
death before the tissue was processed. This important
finding is in line with previously published findings [29],
even though the average PMD of the samples used in
the study by Olah et al. in most cases far exceeded our
average PMD of 6.7 h. This implies that brain autopsies
with long (>12 h) PMDs are still of value to microglia
isolations. Combined, this supports the fact that micro-
glia isolations can also be performed by research groups
that do not have access to tissue samples within hours
after autopsy. Although the average time between death
and tissue processing throughout our samples was only
20.8 h, a number of isolations were performed up to
70 h after death, which still yielded viable microglia. Fi-
nally, we show that donor age does not influence the
microglia yield. Throughout Fig. 3, the combined data
are shown for isolations performed using either the pre-
viously published or current method. Although the aver-
age number of cells/g tissue is higher using the current
method, we observed no significant differences between
both methods in terms of yield. The currently described
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method should be preferred however, since it is faster
and yields similar or higher microglia numbers.
Microglia phenotype
Since CD11b does not discriminate between microglia
and macrophages and no specific human extracellular
microglia marker has been described to date, we wanted
to ensure that the CD11b+ populations isolated from both
WM and GM samples are indeed microglia and are not
reflecting the presence of infiltrated macrophages in the
parenchyma. Although we have previously shown that
macrophages isolated from CP are distinguishable from
microglia by size, granularity, and CD45/CD11b expres-
sion [25, 26], these analyses were performed on separately
isolated populations of cells. To further strengthen the no-
tion that macrophages are not the source of CNS paren-
chymal CD11b+ cells, we developed a way to study both
macrophages and microglia in one population. By fluores-
cently labeling the autologous CD11b+ population isolated
from CP tissue, and spiking these cells in the parenchymal
CD11b+ population before minimal phenotyping, we show
that microglia and macrophages can be easily distin-
guished within the same population of cells, by size,
granularity and CD45/CD11b expression, similar to find-
ings in murine microglia [22].
The main reason to use an acute and direct purification
of microglia from post-mortem CNS samples is to ex-
clude phenotypical changes induced in these cells by pro-
longed adherence steps used in other isolation protocols
[11, 14, 31] as was shown two decades ago by Becher and
Antel [2]. Any phenotypical change detected in acutely
isolated populations should therefore be relevant to the
neuropathological status or CNS location of the samples
from which the cells were extracted. We observed a sig-
nificant difference in CD45 expression, but not CD11b
expression when comparing WM and GM microglia from
control donors. This finding is in line with the notion of
region-specific microglia phenotypes described recently
[13, 18] as well as a recent study showing different ex-
pression profiles for human microglia from cortex and
WM [27]. We show that microglia isolated from MS WM
can be distinguished from microglia from control donors
based on CD45 expression, reflecting an alerted state
[26], as human microglia are known to increase the ex-
pression of specific CD45 isoforms upon immune activa-
tion [8]. However, the MS donor group, due to disease
characteristics and autopsy protocol respectively, also sig-
nificantly deviates from the control group in age and
PMD. It is therefore crucial to be aware of any effect of
clinical parameters (other than neurological) on microglia
phenotype. Our data clearly show that none of the param-
eters investigated (PMD, donor age, CSF pH, total time
until isolation, and cell viability) had a significant effect
on the minimal phenotype. The only exception to these
observations was the CD11b expression of GM microglia,
for which a positive correlation with PMD was found.
These findings strengthen the notion that microglial
changes found in acutely isolated populations can be reli-
ably attributed to the neuropathological status of the CNS
sample. That being said, clinical parameters in donor
groups should be carefully considered, especially for GM
microglia comparisons. Furthermore, care should be
taken when comparing microglia phenotypes between
studies using different isolation methods. We made use of
two similar methods where the main difference is the use
of either trypsin or collagenase I, both of which are widely
used for tissue digestion. Although no differences were
apparent in WM microglia phenotype, GM microglia ap-
pear to be more sensitive to the choice of method, show-
ing increased CD45 and CD11b immunoreactivity with
the current method. Although our sample size for this
comparison was small, this could reflect a differential sen-
sitivity of differentiating markers to enzymatic cleavage in
WM and GM microglia.
In vitro culture and cryogenic storage of primary
microglia
The immediate analysis of the proteome or transcriptome
of acutely isolated microglia will continue to be the most
accurate reflection of microglial phenotype in situ. How-
ever, functional assays using primary human microglia
could provide a unique tool to study functional microglial
responses to various stimuli in vitro, either related to
neurological disease mechanisms or therapeutic interven-
tions. To understand the outcomes of these types of study,
it is crucial to map microglial changes after isolation and
during various culturing methods. Our group has previ-
ously shown the potential for short-term culture of pri-
mary human microglia up to 72 h, in which microglia
retain functional properties as evidenced by myelin phago-
cytosis [20] and response to inflammatory stimuli [25, 27].
We here show that primary WM microglia, in contrast to
GM microglia, can be maintained in culture for up to
10 days without overt cell death, and that functional
phagocytosis of human myelin can still be induced after 5
culture days. The difference in culturing potential between
WM and GM microglia was a surprising finding, as cul-
turing protocols for human GM microglia have been de-
scribed [14, 31], although mainly for CNS surgery
obtained samples. This might reflect a critical time win-
dow post-mortem for GM samples after which the micro-
environment no longer permits microglia to adhere in
culture. Prolonged, or even very short-term culture will
have an effect on microglia behavior. This was addressed
recently using murine microglia [5, 6], showing the de-
pendence of primary microglia on TGF-beta stimulation
to maintain a resting microglia expression profile. Using a
select set of genes, we were able to identify major changes
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in the microglial gene expression due to 4 days of basal cul-
ture using primary microglia from multiple brain donors.
Although no evident pro- or anti-inflammatory profile
could be distinguished, it was clear that the widely used
microglia markers P2RY12 [5] and CX3CR1 [17] were
decreased in expression level. In contrast, the lipopolysac-
charide co-receptor CD14 was highly upregulated, as we
and others have shown before with increasing culture time
[2, 25]. Our data show that cultured human microglia can
be readily used in functional experiments, but it should be
stressed that cultured microglia can no longer be compared
to their acutely analyzed counterparts. Whether specific
culture conditions like the addition of TGFβ1 are also able
to skew cultured human microglia to a more resting-like
phenotype warrants further investigation. An alternative
isolation method to obtain pure populations of primary hu-
man microglia from autopsy tissue was recently described,
relying on the adherent properties of microglia [31]. When
purifying microglia for functional experiments, total cell
yield becomes especially important, so the choice of isola-
tion method must be determined by the downstream appli-
cation. Finally, we explored the possibility of cryogenically
storing primary microglia for biobanking purposes. This
would allow researchers without direct access to unfixed
brain autopsy samples to work with primary human micro-
glia, enhancing the amount of possible scientific investiga-
tion. We here show that although cell recovery after
cryogenic storage is variable, high quality RNA can still be
extracted after cryogenic storage, and minimal cellular phe-
notyping is still possible. Since we do show effects of cryo-
genic storage on CD45 expression, acutely analyzed
microglia and cryogenically stored microglia should not be
compared directly.
Conclusions
In summary, we show that changes in microglial pheno-
type, analyzed in an extensive collection of acutely
isolated microglia, can be attributed to neurological
diagnosis rather than reflect normal variation in ante-
and post-mortem parameters. This finding is of critical
importance to published and future studies revolving
around the characterization of acute cell isolations from
human neurological specimens.
Additional file
Additional file 1: Additional file one contains all supplemental
information mentioned in this manuscript: supplemental table 1,
supplemental figures 1-8, and the detailed microglia isolation protocol
description. (PDF 320 kb)
Acknowledgements
We would like to thank the whole team of the Netherlands Brain Bank
(www.brainbank.nl) for their work and contributions, and Dr. Corbert van
Eden for input during scientific discussions.
Funding
The psychiatry program of the Netherlands Brain Bank (www.nbb-psy.nl) is
funded by grant 240-921200 from the Netherlands Organization for Scientific
Research (NWO).
Availability of data and materials
The dataset used in the current study containing donor parameters and
microglia yield is available from the corresponding author on reasonable
request.
Authors’ contributions
In order of the author list: MM wrote the manuscript and performed and
interpreted all analyses. SM and MP contributed to the writing and
proofreading the manuscript. AA performed the culture experiments. KS
performed the bulk of the microglia isolations. MS was critical in setting up
the new isolation method. JM was critical in setting up the previous isolation
method. JS and DH performed myelin and microglia isolations. KH assisted
with analysis on the BD FACS-Canto II. JH and IH supervised all of the work
and provided feedback on the manuscript. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The Netherlands Brain Bank received permission to perform autopsies and to
use tissue and medical records from the Ethical Committee of the VU
University medical center (VUmc, Amsterdam, The Netherlands). All donors
have given informed consent for autopsy and use of their brain tissue for
research purposes.
Author details
1Netherlands Brain Bank, Netherlands Institute for Neuroscience, Amsterdam,
The Netherlands. 2Department of Neuroimmunology, Netherlands Institute
for Neuroscience, Amsterdam, The Netherlands. 3Department of Astrocyte
Biology and Neurodegeneration, Netherlands Institute for Neuroscience,
Amsterdam, The Netherlands. 4Department of Experimental Immunology,
Academic Medical Center, University of Amsterdam, Amsterdam, The
Netherlands.
Received: 5 February 2017 Accepted: 5 February 2017
References
1. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FMV (2007) Local self-
renewal can sustain CNS microglia maintenance and function throughout
adult life. Nat Neurosci 10:1538–1543. doi:10.1038/nn2014
2. Becher B, Antel JP (1996) Comparison of phenotypic and functional
properties of immediately ex vivo and cultured human adult microglia.
Glia 18:1–10. doi:10.1002/(SICI)1098-1136(199609)18:1<1::AID-GLIA1>3.0.CO;2-6
3. Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC,
Steiner J, Connor TJ, Harkin A, Versnel MA, Drexhage HA (2012) The immune
theory of psychiatric diseases: a key role for activated microglia and circulating
monocytes. J Leukoc Biol 92:959–975. doi:10.1189/jlb.0212100
4. Bruttger J, Karram K, Wörtge S, Regen T, Marini F, Hoppmann N, Klein M,
Blank T, Yona S, Wolf Y, Mack M, Pinteaux E, Müller W, Zipp F, Binder H,
Bopp T, Prinz M, Jung S, Waisman A (2015) Genetic cell ablation reveals
clusters of local self-renewing microglia in the mammalian central nervous
system. Immunity 43:92–106. doi:10.1016/j.immuni.2015.06.012
5. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G,
Koeglsperger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z,
Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL (2014)
Identification of a unique TGF-β-dependent molecular and functional
signature in microglia. Nat Neurosci 17:131–143. doi:10.1038/nn.3599
6. Buttgereit A, Lelios I, Yu X, Vrohlings M, Krakoski NR, Gautier EL, Nishinakamura R,
Becher B, Greter M (2016) Sall1 is a transcriptional regulator defining microglia
identity and function. Nat Immunol. doi:10.1038/ni.3585
Mizee et al. Acta Neuropathologica Communications  (2017) 5:16 Page 13 of 14
7. Chung W-S, Welsh CA, Barres BA, Stevens B (2015) Do glia drive
synaptic and cognitive impairment in disease? Nat Neurosci 18:1539–1545.
doi:10.1038/nn.4142
8. Cosenza-Nashat MA, Kim M-O, Zhao M-L, Suh H-S, Lee SC (2006) CD45
isoform expression in microglia and inflammatory cells in HIV-1 encephalitis.
Brain Pathol 16:256–265. doi:10.1111/j.1750-3639.2006.00027.x
9. Crotti A, Ransohoff RM (2016) Microglial physiology and pathophysiology:
insights from genome-wide transcriptional profiling. Immunity 44:505–515.
doi:10.1016/j.immuni.2016.02.013
10. De Groot CJ, Bergers E, Kamphorst W, Ravid R, Polman CH, Barkhof F, van
der Valk P (2001) Post-mortem MRI-guided sampling of multiple sclerosis
brain lesions: increased yield of active demyelinating and (p)reactive lesions.
Brain 124:1635–1645
11. De Groot CJ, Montagne L, Janssen I, Ravid R, Van Der Valk P, Veerhuis R
(2000) Isolation and characterization of adult microglial cells and
oligodendrocytes derived from postmortem human brain tissue. Brain Res
Brain Res Protoc 5:85–94
12. Dick AD, Pell M, Brew BJ, Foulcher E, Sedgwick JD (1997) Direct ex vivo flow
cytometric analysis of human microglial cell CD4 expression: examination of
central nervous system biopsy specimens from HIV-seropositive patients
and patients with other neurological disease. AIDS 11:1699–1708
13. Doorn KJ, Brevé JJP, Drukarch B, Boddeke HW, Huitinga I, Lucassen PJ,
van Dam A-M (2015) Brain region-specific gene expression profiles in freshly
isolated rat microglia. Front Cell Neurosci 9:84. doi:10.3389/fncel.2015.00084
14. Durafourt BA, Moore CS, Blain M, Antel JP (2013) Isolating, culturing, and
polarizing primary human adult and fetal microglia. Methods Mol Biol 1041:
199–211. doi:10.1007/978-1-62703-520-0_19
15. Durrenberger PF, Fernando S, Kashefi SN, Ferrer I, Hauw J-J, Seilhean D,
Smith C, Walker R, Al-Sarraj S, Troakes C, Palkovits M, Kasztner M, Huitinga I,
Arzberger T, Dexter DT, Kretzschmar H, Reynolds R (2010) Effects of
antemortem and postmortem variables on human brain mRNA quality: a
BrainNet Europe study. J Neuropathol Exp Neurol 69:70–81. doi:10.1097/
NEN.0b013e3181c7e32f
16. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF,
Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M (2010) Fate
mapping analysis reveals that adult microglia derive from primitive
macrophages. Science 330:841–845. doi:10.1126/science.1194637
17. Goldmann T, Wieghofer P, Müller PF, Wolf Y, Varol D, Yona S, Brendecke SM,
Kierdorf K, Staszewski O, Datta M, Luedde T, Heikenwalder M, Jung S, Prinz M
(2013) A new type of microglia gene targeting shows TAK1 to be pivotal in CNS
autoimmune inflammation. Nat Neurosci 16:1618–1626. doi:10.1038/nn.3531
18. Grabert K, Michoel T, Karavolos MH, Clohisey S, Baillie JK, Stevens MP,
Freeman TC, Summers KM, McColl BW (2016) Microglial brain region-
dependent diversity and selective regional sensitivities to aging. Nat
Neurosci 19:504–516. doi:10.1038/nn.4222
19. Hardy JA, Wester P, Winblad B, Gezelius C, Bring G, Eriksson A (1985) The
patients dying after long terminal phase have acidotic brains; implications for
biochemical measurements on autopsy tissue. J Neural Transm 61:253–264
20. Hendrickx DAE, Schuurman KG, van Draanen M, Hamann J, Huitinga I (2014)
Enhanced uptake of multiple sclerosis-derived myelin by THP-1
macrophages and primary human microglia. J Neuroinflammation 11:64.
doi:10.1186/1742-2094-11-64
21. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL,
Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA,
Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A,
Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan
NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E,
Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP (2015)
Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14:388–405. doi:10.
1016/S1474-4422(15)70016-5
22. Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang L, Means TK, El
Khoury J (2013) The microglial sensome revealed by direct RNA sequencing.
Nat Neurosci 16:1896–1905. doi:10.1038/nn.3554
23. Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, Wieghofer P,
Heinrich A, Riemke P, Hölscher C, Müller DN, Luckow B, Brocker T, Debowski K,
Fritz G, Opdenakker G, Diefenbach A, Biber K, Heikenwalder M, Geissmann F,
Rosenbauer F, Prinz M (2013) Microglia emerge from erythromyeloid precursors via
Pu.1- and Irf8-dependent pathways. Nat Neurosci 16:273–280. doi:10.1038/nn.3318
24. Mahad DH, Trapp BD, Lassmann H (2015) Pathological mechanisms in
progressive multiple sclerosis. Lancet Neurol 14:183–193. doi:10.1016/
S1474-4422(14)70256-X
25. Melief J, Koning N, Schuurman KG, Van De Garde MDB, Smolders J, Hoek RM,
Van Eijk M, Hamann J, Huitinga I (2012) Phenotyping primary human microglia:
tight regulation of LPS responsiveness. Glia 60:1506–1517. doi:10.1002/glia.22370
26. Melief J, Schuurman KG, van de Garde MDB, Smolders J, van Eijk M,
Hamann J, Huitinga I (2013) Microglia in normal appearing white matter of
multiple sclerosis are alerted but immunosuppressed. Glia 61:1848–1861.
doi:10.1002/glia.22562
27. Melief J, Sneeboer MAM, Litjens M, Ormel PR, Palmen SJMC, Huitinga I,
Kahn RS, Hol EM, de Witte LD (2016) Characterizing primary human
microglia: a comparative study with myeloid subsets and culture models.
Glia. 1–12. doi:10.1002/glia.23023
28. Mittelbronn M, Dietz K, Schluesener HJ, Meyermann R (2001) Local distribution
of microglia in the normal adult human central nervous system differs by up
to one order of magnitude. Acta Neuropathol 101:249–255
29. Olah M, Raj D, Brouwer N, De Haas AH, Eggen BJL, Den Dunnen WFA,
Biber KPH, Boddeke HWGM (2012) An optimized protocol for the acute
isolation of human microglia from autopsy brain samples. Glia 60:96–111.
doi:10.1002/glia.21251
30. Perry VH, Holmes C (2014) Microglial priming in neurodegenerative disease.
Nat Rev Neurol 10:217–224. doi:10.1038/nrneurol.2014.38
31. Rustenhoven J, Park TI-H, Schweder P, Scotter J, Correia J, Smith AM,
Gibbons HM, Oldfield RL, Bergin PS, Mee EW, Faull RLM, Curtis MA, Scott
Graham E, Dragunow M (2016) Isolation of highly enriched primary human
microglia for functional studies. Sci Rep 6:19371. doi:10.1038/srep19371
32. Salter MW, Beggs S (2014) Sublime microglia: expanding roles for the
guardians of the CNS. Cell 158:15–24. doi:10.1016/j.cell.2014.06.008
33. Sanchez-Guajardo V, Tentillier N, Romero-Ramos M (2015) The relation
between α-synuclein and microglia in Parkinson’s disease: Recent
developments. Neuroscience 302:47–58. doi:10.1016/j.neuroscience.2015.02.008
34. Schafer DP, Stevens B (2015) Microglia function in central nervous system
development and plasticity. Cold Spring Harb Perspect Biol 7:a020545.
doi:10.1101/cshperspect.a020545
35. Schulz C, Perdiguero EG, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K,
Prinz M, Wu B, Jacobsen SEW, Pollard JW, Frampton J, Liu KJ, Geissmann F
(2012) A lineage of myeloid cells independent of Myb and hematopoietic
stem cells. Science (80-) 336:86–90. doi:10.1126/science.1219179
36. Schwartz M, Butovsky O, Brück W, Hanisch U-K (2006) Microglial phenotype: is the
commitment reversible? Trends Neurosci 29:68–74. doi:10.1016/j.tins.2005.12.005
37. Sedgwick JD, Schwender S, Imrich H, Dörries R, Butcher GW, ter Meulen V
(1991) Isolation and direct characterization of resident microglial cells from
the normal and inflamed central nervous system. Proc Natl Acad Sci U S A
88:7438–7442
38. Smith AM, Dragunow M (2014) The human side of microglia. Trends Neurosci
37:125–135. doi:10.1016/j.tins.2013.12.001
39. Wieghofer P, Prinz M (2015) Genetic manipulation of microglia during brain
development and disease. Biochim Biophys Acta - Mol Basis Dis 1862:299–309.
doi:10.1016/j.bbadis.2015.09.019
40. Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H,
Steinberg GK, Edwards MSB, Li G, Duncan JA, Cheshier SH, Shuer LM, Chang EF,
Grant GA, Gephart MGH, Barres BA (2015) Purification and characterization of
progenitor and mature human astrocytes reveals transcriptional and functional
differences with mouse. Neuron 89:37–53. doi:10.1016/j.neuron.2015.11.013
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mizee et al. Acta Neuropathologica Communications  (2017) 5:16 Page 14 of 14
